Skip to main content

Table 1 Clinical characteristics of the 65 examined patients with WD

From: Comparative assessment of clinical rating scales in Wilson’s disease

 

N

Percentage

Median

Range

Gender

 Female

33

50.8

  

 Male

32

49.2

  

Age at assessment (yr)

 All

  

35

15–62

 Female

  

40

15–62

 Male

  

29.5

16–62

Age at onset of symptoms (yr)

  

16

1–47

Age at time of diagnosis (yr)

  

17

3–54

Initial mode of manifestation

 Hepatic

46

70.8

  

 Hepatic + neurological

10

15.4

  

 Neurological

6

9.2

  

 Asymptomatic

3

4.6

  

Liver cirrhosis at time of diagnosis

21

32.3

  

By initial mode of manifestation

  Hepatic [n = 46]

15

32.6

  

  Hepatic + neurological [n = 10]

6

60.0

  

Liver status at assessment

 MELD score [missing data n = 4]

  

7.3

6–17

 Child-Pugh score [missing data n = 7]

  

5

5–11

KFR at time of diagnosis [missing data n = 8]

28

49.1

  

KFR at assessment

19

29.2

  

Treatment at assessment in all patients (n = 65)

 D-Penicillamine

38

58.5

  

 Trientine

16

24.6

  

 Zinc

7

10.8

  

 D-Penicillamine + zinc

2

3.1

  

 Trientine + zinc

2

3.1

  

Treatment at assessment in neurologically symptomatic patients (n = 16)

 Chelating agents

13

81.2

  

 Zinc with or without chelating agent

3

18.8

  

Duration of treatment (yr)

  

15

0.4–47

  1. Abbreviations: KFR Kayser-Fleischer ring, pts. patients, yr. years